Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM6T924)

Drug Name
Gabapentin Drug Info
Synonyms
Aclonium; GBN; Gabapen; Gabapentina; Gabapentine; Gabapentinium; Gabapentino; Gabapentinum; Gabapetin; Neurontin; Serada; Vultin; Apotex brand of gabapentin; Aventis brand of gabapentin; Gabapentin GR; Gabapentin Hexal; Gabapentin Stada; Gabapentino [Spanish]; Hexal brand of gabapentin; Novopharm brand of gabapentin; Parke Davis brand of gabapentin; Pfizer brand of gabapentin; Pharmascience brand of gabapentin; Ratiopharm brand of gabapentin; Stadapharm brand of gabapentin; GOE 2450; Go 3450; Apo-Gabapentin; DDS-2003; DM-1796; DM-5689; G-154; Gabapentin (Neurontin); Gabapentin-ratiopharm; Gabapentine [INN-French]; Gabapentino [INN-Spanish]; Gabapentinum [INN-Latin]; Goe-3450; Neurontin (TN); Novo-Gabapentin; PMS-Gabapentin; Warner-Lambert brand of gabapentin; Gabapentin [USAN:INN:BAN]; [1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID; Gabapentin (JAN/USAN/INN); 1-(Aminomethyl)-cyclohexaneacetic acid; 1-(Aminomethyl)cyclohexaneacetic acid; 2-[1-(aminomethyl)cyclohexyl]acetic acid
Therapeutic ClassAnalgesics
Cross-matching ID
PubChem CID
3446
ChEBI ID
CHEMBL940
CAS Number
CAS 60142-96-3
TTD Drug ID
D0J0ZS
VARIDT Drug ID
DR00217
ACDINA Drug ID
D00296

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Complement and coagulation cascades 2.13 0.00e+0 76/85 (89.41%) FGG;CFH;SERPINA5;...
Tryptophan metabolism 1.85 2.41e-2 35/42 (83.33%) DLD;AOC1;ECHS1;...
Mitophagy -1.62 4.90e-2 56/68 (82.35%) TBC1D17;BNIP3L;RRAS;...
Relaxin signaling pathway -1.63 4.85e-2 114/129 (88.37%) PIK3CA;RLN1;GNG5;...
Oxytocin signaling pathway -1.63 4.99e-2 128/154 (83.12%) PLA2G4A;PPP3CA;OXTR;...
cGMP-PKG signaling pathway -1.65 4.61e-2 145/167 (86.83%) CREB3L1;PPP3CA;MEF2A;...
Gap junction -1.66 4.37e-2 72/88 (81.82%) PRKCA;PLCB4;RAF1;...
Various types of N-glycan biosynthesis -1.66 4.57e-2 26/39 (66.67%) MAN1A1;MGAT1;B4GALT2;...
Allograft rejection -1.66 4.55e-2 32/38 (84.21%) HLA-DMB;TNF;HLA-DPA1;...
Mucin type O-glycan biosynthesis -1.67 4.60e-2 20/36 (55.56%) GALNT1;ST6GALNAC2;GCNT3;...
GnRH signaling pathway -1.67 4.78e-2 80/93 (86.02%) PLA2G4C;MAPK9;CDC42;...
Bacterial invasion of epithelial cells -1.67 4.92e-2 59/77 (76.62%) CLTA;ARPC4;PXN;...
Arrhythmogenic right ventricular cardiomyopathy -1.69 4.72e-2 70/77 (90.91%) RYR2;ACTN3;SGCG;...
Long-term potentiation -1.70 4.41e-2 61/67 (91.04%) RPS6KA2;PRKCA;PLCB4;...
Amoebiasis -1.72 3.85e-2 99/102 (97.06%) LAMB2;SERPINB9;RAB7A;...
Glucagon signaling pathway -1.73 3.63e-2 89/107 (83.18%) LDHB;CAMK2G;CREB1;...
Growth hormone synthesis, secretion and action -1.74 3.99e-2 108/119 (90.76%) CREB3L1;PIK3CA;PTK2;...
Cortisol synthesis and secretion -1.74 3.74e-2 58/65 (89.23%) CREB3L1;AGT;KCNK3;...
Adrenergic signaling in cardiomyocytes -1.75 4.05e-2 130/150 (86.67%) CREB3L1;AGT;MYH7;...
Circadian entrainment -1.78 3.74e-2 85/97 (87.63%) PER1;RYR1;PRKCA;...
Calcium signaling pathway -1.79 3.95e-2 213/240 (88.75%) CAMK1;CALML3;CACNA1S;...
Insulin secretion -1.86 2.25e-2 75/86 (87.21%) PCLO;ATP1B3;KCNMB1;...
Aldosterone synthesis and secretion -1.91 1.56e-2 85/98 (86.73%) CREB3L1;AGT;KCNK3;...
Hypertrophic cardiomyopathy -1.98 1.25e-2 81/90 (90%) SGCA;ITGA8;IL6;...
Gastric acid secretion -1.99 1.87e-2 63/76 (82.89%) ATP1B3;SST;PRKCA;...
Dilated cardiomyopathy -2.07 0.00e+0 86/96 (89.58%) SGCA;ITGA8;ITGA5;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 3.33uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 20uM 72H
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H